Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-23

AUTHORS

Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, Jun Zhu, Guodong Lu, Stefan Liebscher, Chunxiao Cai

ABSTRACT

BACKGROUND: Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE: As the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate were Asian, this study investigated the safety and efficacy of pralatrexate as monotherapy in Chinese patients with R/R PTCL. PATIENTS AND METHODS: In this single-arm, open-label, multicenter study, 71 patients with R/R PTCL (median [range] 2 [1-14] prior systemic treatments) were recruited from 15 centers in China and received pralatrexate IV 30 mg/m2/week for 6 weeks in 7-week cycles (with vitamin B12/folate). The primary endpoint was objective response rate (ORR) per central review (null hypothesis: ORR < 15%). RESULTS: The study's primary objective was met: ORR (95% CI) was 52% (40-64%) (p < 0.001) and responses were observed across pre-specified patient subgroups. Median (95% CI) duration of response was 8.7 (3.3-14.1) months and first response was observed in Cycle 1 for most (84%) patients. Median (95% CI) progression-free survival and overall survival was 4.8 (3.1-8.1) months and 18.0 (10.4-NA) months, respectively. The most common treatment-emergent adverse events were stomatitis (68% [Grade 3/4: 20%]), anemia (49% [Grade 3/4: 24%]) and alanine aminotransferase increase (41% [Grade 3/4: 4%]). CONCLUSIONS: These results demonstrate that pralatrexate may represent a promising treatment option for Chinese patients with R/R PTCL. The ORR of 52% compared favorably with prior studies of pralatrexate in other populations and there were no unanticipated side effects. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03349333. More... »

PAGES

1-10

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y

DOI

http://dx.doi.org/10.1007/s11523-019-00630-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112965789

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30904980


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Fudan University Shanghai Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.452404.3", 
          "name": [
            "Fudan University Shanghai Cancer Center, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hong", 
        "givenName": "Xiaonan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, 100142, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Song", 
        "givenName": "Yuqin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sun Yat-sen University Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.488530.2", 
          "name": [
            "Sun Yat-sen University Cancer Center, Guangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "Huiqiang", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sun Yat-sen University Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.488530.2", 
          "name": [
            "Sun Yat-sen University Cancer Center, Guangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bai", 
        "givenName": "Bing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Tianjin Medical University Cancer Institute and Hospital, Tianjin, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Huilai", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peking University Third Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411642.4", 
          "name": [
            "Peking University Third Hospital, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ke", 
        "givenName": "Xiaoyan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peking Union Medical College Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413106.1", 
          "name": [
            "National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shi", 
        "givenName": "Yuankai", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, 100142, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Jun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Mundipharma (China) Pharmaceutical Co., Ltd, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lu", 
        "givenName": "Guodong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mundipharma (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.476538.b", 
          "name": [
            "Mundipharma Research GmbH & Co. KG, Limburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liebscher", 
        "givenName": "Stefan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Mundipharma (China) Pharmaceutical Co., Ltd, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cai", 
        "givenName": "Chunxiao", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s13045-016-0243-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000335967", 
          "https://doi.org/10.1186/s13045-016-0243-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13045-016-0243-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000335967", 
          "https://doi.org/10.1186/s13045-016-0243-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1309/ajcp7yltqpusdq5c", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006957284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.29.9024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007463841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.59.2782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010415946"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv237", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010781265"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2016-01-643569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023194534"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.4558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029891295"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030092573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-12-542142", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031182649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1746-1596-6-77", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033104303", 
          "https://doi.org/10.1186/1746-1596-6-77"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-014-1520-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034106275", 
          "https://doi.org/10.1007/s12185-014-1520-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv201", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038078668"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2014-04-573089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047085552"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.7524", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050309061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5402/2011/623924", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053736943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.63.5540", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204432"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.4.1244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13045-017-0439-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084251896", 
          "https://doi.org/10.1186/s13045-017-0439-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13045-017-0439-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084251896", 
          "https://doi.org/10.1186/s13045-017-0439-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3389/fphar.2017.00354", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085927485"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/cas.13340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090995606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.12688/f1000research.12573.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099598065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.12688/f1000research.12573.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099598065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-018-2404-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100752957", 
          "https://doi.org/10.1007/s12185-018-2404-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2018.0007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101015899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2018.0007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101015899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.6004/jnccn.2018.0007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101015899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2017.186577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101833993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2017.186577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101833993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2017.186577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101833993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2017.186577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101833993"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)32984-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110345835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)32984-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110345835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)32984-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110345835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)32984-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110345835"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-23", 
    "datePublishedReg": "2019-03-23", 
    "description": "BACKGROUND: Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL.\nOBJECTIVE: As the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate were Asian, this study investigated the safety and efficacy of pralatrexate as monotherapy in Chinese patients with R/R PTCL.\nPATIENTS AND METHODS: In this single-arm, open-label, multicenter study, 71 patients with R/R PTCL (median [range] 2 [1-14] prior systemic treatments) were recruited from 15 centers in China and received pralatrexate IV 30\u00a0mg/m2/week for 6\u00a0weeks in 7-week cycles (with vitamin B12/folate). The primary endpoint was objective response rate (ORR) per central review (null hypothesis: ORR <\u200915%).\nRESULTS: The study's primary objective was met: ORR (95% CI) was 52% (40-64%) (p\u2009<\u20090.001) and responses were observed across pre-specified patient subgroups. Median (95% CI) duration of response was 8.7 (3.3-14.1) months and first response was observed in Cycle 1 for most (84%) patients. Median (95% CI) progression-free survival and overall survival was 4.8 (3.1-8.1) months and 18.0 (10.4-NA) months, respectively. The most common treatment-emergent adverse events were stomatitis (68% [Grade 3/4: 20%]), anemia (49% [Grade 3/4: 24%]) and alanine aminotransferase increase (41% [Grade 3/4: 4%]).\nCONCLUSIONS: These results demonstrate that pralatrexate may represent a promising treatment option for Chinese patients with R/R PTCL. The ORR of 52% compared favorably with prior studies of pralatrexate in other populations and there were no unanticipated side effects.\nTRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03349333.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11523-019-00630-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study", 
    "pagination": "1-10", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-019-00630-y"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ac55fbec874b125b18b8944bcd98b0a80f653cf069b083ba2b607a771d4f96d4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112965789"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101270595"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30904980"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-019-00630-y", 
      "https://app.dimensions.ai/details/publication/pub.1112965789"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T08:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000374_0000000374/records_119717_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11523-019-00630-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-019-00630-y'


 

This table displays all metadata directly associated to this object as RDF triples.

231 TRIPLES      21 PREDICATES      53 URIs      20 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-019-00630-y schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N7db4610bbeb4425aa1fbbe5c32aea54a
4 schema:citation sg:pub.10.1007/s12185-014-1520-3
5 sg:pub.10.1007/s12185-018-2404-8
6 sg:pub.10.1186/1746-1596-6-77
7 sg:pub.10.1186/s13045-016-0243-8
8 sg:pub.10.1186/s13045-017-0439-6
9 https://doi.org/10.1016/s0140-6736(18)32984-2
10 https://doi.org/10.1093/annonc/mdv201
11 https://doi.org/10.1093/annonc/mdv237
12 https://doi.org/10.1111/cas.13340
13 https://doi.org/10.1158/1078-0432.ccr-12-2251
14 https://doi.org/10.1182/blood-2013-12-542142
15 https://doi.org/10.1182/blood-2014-04-573089
16 https://doi.org/10.1182/blood-2016-01-643569
17 https://doi.org/10.1200/jco.1999.17.4.1244
18 https://doi.org/10.1200/jco.2008.16.4558
19 https://doi.org/10.1200/jco.2010.29.9024
20 https://doi.org/10.1200/jco.2012.44.7524
21 https://doi.org/10.1200/jco.2014.59.2782
22 https://doi.org/10.1200/jco.2015.63.5540
23 https://doi.org/10.12688/f1000research.12573.1
24 https://doi.org/10.1309/ajcp7yltqpusdq5c
25 https://doi.org/10.3324/haematol.2017.186577
26 https://doi.org/10.3389/fphar.2017.00354
27 https://doi.org/10.5402/2011/623924
28 https://doi.org/10.6004/jnccn.2018.0007
29 schema:datePublished 2019-03-23
30 schema:datePublishedReg 2019-03-23
31 schema:description BACKGROUND: Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE: As the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate were Asian, this study investigated the safety and efficacy of pralatrexate as monotherapy in Chinese patients with R/R PTCL. PATIENTS AND METHODS: In this single-arm, open-label, multicenter study, 71 patients with R/R PTCL (median [range] 2 [1-14] prior systemic treatments) were recruited from 15 centers in China and received pralatrexate IV 30 mg/m2/week for 6 weeks in 7-week cycles (with vitamin B12/folate). The primary endpoint was objective response rate (ORR) per central review (null hypothesis: ORR < 15%). RESULTS: The study's primary objective was met: ORR (95% CI) was 52% (40-64%) (p < 0.001) and responses were observed across pre-specified patient subgroups. Median (95% CI) duration of response was 8.7 (3.3-14.1) months and first response was observed in Cycle 1 for most (84%) patients. Median (95% CI) progression-free survival and overall survival was 4.8 (3.1-8.1) months and 18.0 (10.4-NA) months, respectively. The most common treatment-emergent adverse events were stomatitis (68% [Grade 3/4: 20%]), anemia (49% [Grade 3/4: 24%]) and alanine aminotransferase increase (41% [Grade 3/4: 4%]). CONCLUSIONS: These results demonstrate that pralatrexate may represent a promising treatment option for Chinese patients with R/R PTCL. The ORR of 52% compared favorably with prior studies of pralatrexate in other populations and there were no unanticipated side effects. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03349333.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf Nb451afcc37dc4552a61f6fd1b740f1ef
36 Nbd0ac2860f864c8989e277373fa0bccb
37 sg:journal.1036678
38 schema:name Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
39 schema:pagination 1-10
40 schema:productId N0cad0303c8e54a028a8ba54511191425
41 N8f4348a922934a39aed5fe95a546fb7b
42 Nb91b834a589e4a178baabf9808ef2180
43 Ndad9ef7f88b54d439067f58d6569860d
44 Nf21945d5eaa248cb9aa338c506e22db8
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112965789
46 https://doi.org/10.1007/s11523-019-00630-y
47 schema:sdDatePublished 2019-04-15T08:48
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher Na9607f86842244fc9e27ee850be2b89f
50 schema:url https://link.springer.com/10.1007%2Fs11523-019-00630-y
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N0cad0303c8e54a028a8ba54511191425 schema:name nlm_unique_id
55 schema:value 101270595
56 rdf:type schema:PropertyValue
57 N1aba05df5fdf41fa89717bd2ad2925cc schema:name Mundipharma (China) Pharmaceutical Co., Ltd, Beijing, China
58 rdf:type schema:Organization
59 N1bcb557bed314a81828e100d175a7ab3 schema:affiliation Na270bb7bf6114f4591473cdaa20f0aa0
60 schema:familyName Song
61 schema:givenName Yuqin
62 rdf:type schema:Person
63 N2e94cfe0e22a47039e9bd3a4a049a036 rdf:first Nf058132c808b4a5cb0c2e2fe5b058a65
64 rdf:rest rdf:nil
65 N32b350435e304f668803065076f96796 schema:affiliation https://www.grid.ac/institutes/grid.488530.2
66 schema:familyName Bai
67 schema:givenName Bing
68 rdf:type schema:Person
69 N39b386eb55b6472e83a49348ade11ec4 schema:affiliation N5894a065c4ba4854aef19b6a39393fe0
70 schema:familyName Zhu
71 schema:givenName Jun
72 rdf:type schema:Person
73 N4e8554f2d3094d2e83e6996c2b2315f2 rdf:first N9f7e96a07571452db971f743b3aa46fc
74 rdf:rest Naa470b54d21444f7a2f515ae472c8aed
75 N5894a065c4ba4854aef19b6a39393fe0 schema:name Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, 100142, Beijing, China
76 rdf:type schema:Organization
77 N685da840c358497f9e9667ace11fc03f schema:affiliation https://www.grid.ac/institutes/grid.413106.1
78 schema:familyName Shi
79 schema:givenName Yuankai
80 rdf:type schema:Person
81 N7db4610bbeb4425aa1fbbe5c32aea54a rdf:first Nf4b4b29361e14b44a7c456d403592b1c
82 rdf:rest Nab29fbae2e8440d69f3026bb178a3364
83 N7ec1cae8c225433b97c69ec4538ccbf4 schema:affiliation https://www.grid.ac/institutes/grid.476538.b
84 schema:familyName Liebscher
85 schema:givenName Stefan
86 rdf:type schema:Person
87 N8250a52725064198a1683bed838464b3 rdf:first Na5fe68c51c704c0780aa7743fade1706
88 rdf:rest N9ccd0f385cf44ac59727a2dcc5e06faa
89 N85756ce75ddc40dcbcd8e6d2ec0b03d3 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
90 schema:familyName Zhang
91 schema:givenName Huilai
92 rdf:type schema:Person
93 N871786df193a48c98b337dd5260c217b rdf:first N685da840c358497f9e9667ace11fc03f
94 rdf:rest Nf4f9995962344c088748eadd541c622a
95 N8f4348a922934a39aed5fe95a546fb7b schema:name readcube_id
96 schema:value ac55fbec874b125b18b8944bcd98b0a80f653cf069b083ba2b607a771d4f96d4
97 rdf:type schema:PropertyValue
98 N9aea5edb5da34777a46a0217b2e64389 schema:name Mundipharma (China) Pharmaceutical Co., Ltd, Beijing, China
99 rdf:type schema:Organization
100 N9ccd0f385cf44ac59727a2dcc5e06faa rdf:first N7ec1cae8c225433b97c69ec4538ccbf4
101 rdf:rest N2e94cfe0e22a47039e9bd3a4a049a036
102 N9f7e96a07571452db971f743b3aa46fc schema:affiliation https://www.grid.ac/institutes/grid.488530.2
103 schema:familyName Huang
104 schema:givenName Huiqiang
105 rdf:type schema:Person
106 Na270bb7bf6114f4591473cdaa20f0aa0 schema:name Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, 100142, Beijing, China
107 rdf:type schema:Organization
108 Na5fe68c51c704c0780aa7743fade1706 schema:affiliation N1aba05df5fdf41fa89717bd2ad2925cc
109 schema:familyName Lu
110 schema:givenName Guodong
111 rdf:type schema:Person
112 Na9607f86842244fc9e27ee850be2b89f schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 Naa470b54d21444f7a2f515ae472c8aed rdf:first N32b350435e304f668803065076f96796
115 rdf:rest Nee0dc0f0bd164d3da1a4efcd1b991c15
116 Nab29fbae2e8440d69f3026bb178a3364 rdf:first N1bcb557bed314a81828e100d175a7ab3
117 rdf:rest N4e8554f2d3094d2e83e6996c2b2315f2
118 Nb451afcc37dc4552a61f6fd1b740f1ef schema:volumeNumber 14
119 rdf:type schema:PublicationVolume
120 Nb4680f67954e4f689a034500e2110081 rdf:first Nca119128be9140808af7fda51e39b622
121 rdf:rest N871786df193a48c98b337dd5260c217b
122 Nb91b834a589e4a178baabf9808ef2180 schema:name dimensions_id
123 schema:value pub.1112965789
124 rdf:type schema:PropertyValue
125 Nbd0ac2860f864c8989e277373fa0bccb schema:issueNumber 2
126 rdf:type schema:PublicationIssue
127 Nca119128be9140808af7fda51e39b622 schema:affiliation https://www.grid.ac/institutes/grid.411642.4
128 schema:familyName Ke
129 schema:givenName Xiaoyan
130 rdf:type schema:Person
131 Ndad9ef7f88b54d439067f58d6569860d schema:name doi
132 schema:value 10.1007/s11523-019-00630-y
133 rdf:type schema:PropertyValue
134 Nee0dc0f0bd164d3da1a4efcd1b991c15 rdf:first N85756ce75ddc40dcbcd8e6d2ec0b03d3
135 rdf:rest Nb4680f67954e4f689a034500e2110081
136 Nf058132c808b4a5cb0c2e2fe5b058a65 schema:affiliation N9aea5edb5da34777a46a0217b2e64389
137 schema:familyName Cai
138 schema:givenName Chunxiao
139 rdf:type schema:Person
140 Nf21945d5eaa248cb9aa338c506e22db8 schema:name pubmed_id
141 schema:value 30904980
142 rdf:type schema:PropertyValue
143 Nf4b4b29361e14b44a7c456d403592b1c schema:affiliation https://www.grid.ac/institutes/grid.452404.3
144 schema:familyName Hong
145 schema:givenName Xiaonan
146 rdf:type schema:Person
147 Nf4f9995962344c088748eadd541c622a rdf:first N39b386eb55b6472e83a49348ade11ec4
148 rdf:rest N8250a52725064198a1683bed838464b3
149 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
150 schema:name Medical and Health Sciences
151 rdf:type schema:DefinedTerm
152 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
153 schema:name Clinical Sciences
154 rdf:type schema:DefinedTerm
155 sg:journal.1036678 schema:issn 1776-2596
156 1776-260X
157 schema:name Targeted Oncology
158 rdf:type schema:Periodical
159 sg:pub.10.1007/s12185-014-1520-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034106275
160 https://doi.org/10.1007/s12185-014-1520-3
161 rdf:type schema:CreativeWork
162 sg:pub.10.1007/s12185-018-2404-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100752957
163 https://doi.org/10.1007/s12185-018-2404-8
164 rdf:type schema:CreativeWork
165 sg:pub.10.1186/1746-1596-6-77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033104303
166 https://doi.org/10.1186/1746-1596-6-77
167 rdf:type schema:CreativeWork
168 sg:pub.10.1186/s13045-016-0243-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000335967
169 https://doi.org/10.1186/s13045-016-0243-8
170 rdf:type schema:CreativeWork
171 sg:pub.10.1186/s13045-017-0439-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084251896
172 https://doi.org/10.1186/s13045-017-0439-6
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/s0140-6736(18)32984-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110345835
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1093/annonc/mdv201 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038078668
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1093/annonc/mdv237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010781265
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1111/cas.13340 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090995606
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1158/1078-0432.ccr-12-2251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030092573
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1182/blood-2013-12-542142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031182649
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1182/blood-2014-04-573089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047085552
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1182/blood-2016-01-643569 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023194534
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1200/jco.1999.17.4.1244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549729
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1200/jco.2008.16.4558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029891295
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1200/jco.2010.29.9024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007463841
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1200/jco.2012.44.7524 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050309061
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1200/jco.2014.59.2782 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010415946
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1200/jco.2015.63.5540 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204432
201 rdf:type schema:CreativeWork
202 https://doi.org/10.12688/f1000research.12573.1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099598065
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1309/ajcp7yltqpusdq5c schema:sameAs https://app.dimensions.ai/details/publication/pub.1006957284
205 rdf:type schema:CreativeWork
206 https://doi.org/10.3324/haematol.2017.186577 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101833993
207 rdf:type schema:CreativeWork
208 https://doi.org/10.3389/fphar.2017.00354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085927485
209 rdf:type schema:CreativeWork
210 https://doi.org/10.5402/2011/623924 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053736943
211 rdf:type schema:CreativeWork
212 https://doi.org/10.6004/jnccn.2018.0007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101015899
213 rdf:type schema:CreativeWork
214 https://www.grid.ac/institutes/grid.411642.4 schema:alternateName Peking University Third Hospital
215 schema:name Peking University Third Hospital, Beijing, China
216 rdf:type schema:Organization
217 https://www.grid.ac/institutes/grid.411918.4 schema:alternateName Tianjin Medical University Cancer Institute and Hospital
218 schema:name Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
219 rdf:type schema:Organization
220 https://www.grid.ac/institutes/grid.413106.1 schema:alternateName Peking Union Medical College Hospital
221 schema:name National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
222 rdf:type schema:Organization
223 https://www.grid.ac/institutes/grid.452404.3 schema:alternateName Fudan University Shanghai Cancer Center
224 schema:name Fudan University Shanghai Cancer Center, Shanghai, China
225 rdf:type schema:Organization
226 https://www.grid.ac/institutes/grid.476538.b schema:alternateName Mundipharma (Germany)
227 schema:name Mundipharma Research GmbH & Co. KG, Limburg, Germany
228 rdf:type schema:Organization
229 https://www.grid.ac/institutes/grid.488530.2 schema:alternateName Sun Yat-sen University Cancer Center
230 schema:name Sun Yat-sen University Cancer Center, Guangzhou, China
231 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...